ADPT Stock Recent News

ADPT LATEST HEADLINES

ADPT Stock News Image - globenewswire.com

SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2025 after market close on Tuesday, August 5, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

globenewswire.com 2025 Jul 15
ADPT Stock News Image - zacks.com

Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

zacks.com 2025 Jul 04
ADPT Stock News Image - globenewswire.com

clonoSEQ® is now integrated into Flatiron Health's OncoEMR®, simplifying MRD testing access for over 4,500 clinicians across the Flatiron network.

globenewswire.com 2025 Jul 01
ADPT Stock News Image - zacks.com

Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com 2025 Jun 26
ADPT Stock News Image - zacks.com

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com 2025 Jun 13
ADPT Stock News Image - zacks.com

Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.

zacks.com 2025 Jun 11
ADPT Stock News Image - globenewswire.com

SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. These presentations include notable new data supporting the clinical actionability of clonoSEQ in both multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).

globenewswire.com 2025 May 30
ADPT Stock News Image - globenewswire.com

SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL.

globenewswire.com 2025 May 28
ADPT Stock News Image - zacks.com

Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.

zacks.com 2025 May 26
ADPT Stock News Image - zacks.com

Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com 2025 May 09
10 of 50